VBI-2902
{{cs1 config|name-list-style=vanc}}
{{short description|Vaccine candidate against COVID-19}}
{{Use dmy dates|date=March 2021}}
{{Infobox drug
| Verifiedfields =
| verifiedrevid =
| drug_name =
| INN =
| type = vaccine
| image =
| alt =
| caption =
| target = SARS-CoV-2
| vaccine_type = vlp
| pronounce =
| tradename =
| Drugs.com =
| MedlinePlus =
| licence_EU =
| licence_US =
| pregnancy_AU =
| pregnancy_category =
| legal_AU =
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA =
| legal_UK =
| legal_US =
| legal_UN =
| legal_NZ =
| legal_status =
| routes_of_administration = Intramuscular
| CAS_number = 2695526-51-1
| ATCvet =
| ATC_prefix =
| ATC_suffix =
| PubChem =
| DrugBank =
| synonyms = VBI-2902a
}}
{{COVID-19 pandemic sidebar}}
N VBI-2902 is a COVID-19 vaccine candidate developed by Variation Biotechnologies from the United States.{{Cite web|last=Philippidis|first=Alex|date=2021-11-01|title=Six Up-and-Coming COVID-19 Vaccines|url=https://www.genengnews.com/topics/translational-medicine/infectious-diseases/six-up-and-coming-covid-19-vaccines/|access-date=2021-12-23|website=GEN - Genetic Engineering and Biotechnology News|language=en-US}}
History
In early 2020, in collaboration with NRC the VBI's vaccine—VBI-2900—was developed. According to the company, they have two vaccine candidates—"enveloped virus-like particle (eVLP)".{{Cite web| title = VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902| work = VBI Vaccines| access-date = March 22, 2021| date = March 9, 2021| url = https://www.vbivaccines.com/press-releases/enrollment-in-phase-1-2-covid-study/}} VBI-2901 is a "trivalent pan-coronavirus vaccine expressing the SARS-CoV-2, SARS-CoV, and MERS-CoV spike proteins". VBI-2902 is a "monovalent COVID-19-specific vaccine expressing the SARS-CoV-2 spike protein". By March 9, the initial Phase 1/2 study of VBI-2902 was underway.{{Cite web |title=VBI Vaccines Inc: VBI-2902a – COVID19 Vaccine Tracker |url=https://covid19.trackvaccines.org/vaccines/91/ |access-date=2022-03-27 |website=covid19.trackvaccines.org}}{{Cite journal |last=VBI Vaccines Inc. |date=2021-10-01 |title=A Phase 1a/1b, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 (SARS-CoV-2) Vaccine Candidates VBI-2902a and VBI-2905a in Healthy Adults |url=https://clinicaltrials.gov/ct2/show/NCT04773665}} VBI received CA$56 million from the federal government towards the COVID-19 vaccine development.{{Cite podcast |vauthors=Curran M, Sali D, Kovessy P |title=Podcast: Kemptville's next boom, Variation Biotechnologies' $56M injection, Vanier 'gateway' |url=https://obj.ca/article/local/podcast-kemptvilles-next-boom-variation-biotechnologies-56m-injection-vanier-gateway |series=Behind the Headlines |date=August 2020 |access-date=March 22, 2021 |archive-date=2 May 2021 |archive-url=https://web.archive.org/web/20210502170922/https://obj.ca/article/local/podcast-kemptvilles-next-boom-variation-biotechnologies-56m-injection-vanier-gateway |url-status=dead }}
References
{{reflist}}
External links
{{scholia}}
- https://www.vbivaccines.com/press-releases/vbi-2902-preclinical-and-challenge-study-data/
{{Vaccines}}
{{COVID-19 pandemic}}
{{Portal bar | Medicine | Viruses | COVID-19}}
Category:Clinical trials related to COVID-19
Category:Canadian COVID-19 vaccines
Category:Virus-like particle vaccines
{{COVID19-vaccine-stub}}
{{vaccine-stub}}